Temporal Analysis of Serial Donations Reveals Decrease in Neutralizing Capacity and Justifies Revised Qualifying Criteria for Coronavirus Disease 2019 Convalescent Plasma

BACKGROUND: Coronavirus disease 2019 (COVID-19) convalescent plasma (CCP) received an Emergency Use Authorization by the US Food and Drug Administration (FDA). CCP with a signal-to-cutoff ratio of ≥12 using the Ortho VITROS severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immunoglobulin...

Descripción completa

Detalles Bibliográficos
Autores principales: Girardin, Roxie C, Dupuis, Alan P, Payne, Anne F, Sullivan, Timothy J, Strauss, Donna, Parker, Monica M, McDonough, Kathleen A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Major Articles and Brief Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7928872/
https://www.ncbi.nlm.nih.gov/pubmed/33417696
http://dx.doi.org/10.1093/infdis/jiaa803

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7928872/
https://www.ncbi.nlm.nih.gov/pubmed/33417696
http://dx.doi.org/10.1093/infdis/jiaa803

Ejemplares similares